RxDoctor Payments Data

Donald Morris, DO

Ophthalmology · Pittsburgh, PANPI 1336108794

Payments from drug & device makers

$3,828in general payments, 2019–2025

Across 174 payments — averaging $22.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$772
  • Bausch & Lomb Americas Inc.$579
  • AbbVie$408
  • Oyster Point Pharma, Inc.$267
  • Mallinckrodt Hospital Products Inc.$255
  • Tarsus Pharmaceuticals, Inc.$201
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,828100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,828 in reported general payments places this provider in the 70th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$171,135
Medicare patients
710
Services billed
1,595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine86$84,377
LumiganBimatoprost126$51,875
Cyclosporine66$45,192
VyzultaLatanoprostene Bunod69$35,929
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol96$27,310
CombiganBrimonidine Tartrate/Timolol40$18,302
RocklatanNetarsudil Mesylat/Latanoprost24$16,326
MieboPerfluorohexyloctane/Pf22$16,233
Travoprost76$15,098
XiidraLifitegrast18$14,626
Alphagan PBrimonidine Tartrate31$13,403
SimbrinzaBrinzolamide/Brimonidine Tart37$12,638
Timolol Maleate195$7,579
Brimonidine Tartrate158$5,429
Latanoprost381$4,762

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$408$167,958283 claims
Bausch & Lomb Americas Inc.Vyzulta, Miebo, Xiidra$579$66,789109 claims
Aerie Pharmaceuticals, Inc.Rocklatan$95$16,32624 claims
AlconSimbrinza$772$12,63837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →